Vivos Therapeutics Inc. (VVOS) is a Medical/Dental Instruments company listed on NASDAQ. In the last 30 days Quantisnow tracked 13 wire items for VVOS, including 6 SEC filings, 4 press releases and news items and 3 insider trades. The most recent was published Nov 2, 2026.
Financial highlights
Full financials- Revenue, TTM
- $20.90M
- Revenue growth
- +45.2%
- Net income, TTM
- -$25.53M
- Net margin
- -122.1%
- Free cash flow, TTM
- -$19.18M
- Cash
- $1.77M
For the twelve months ended Jun 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks50+160%
2026-05-102026-11-01
Mix3190d
- SEC Filings11(35%)
- Other10(32%)
- Insider7(23%)
- Earnings2(6%)
- Dividends1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by Vivos Therapeutics Inc.DEFA14A - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECSEC Form DEF 14A filed by Vivos Therapeutics Inc.DEF 14A - Vivos Therapeutics, Inc. (0001716166) (Filer)
- INSIDERSEC Form 4 filed by Vivos Therapeutics Inc.4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- INSIDERSEC Form 4 filed by Vivos Therapeutics Inc.4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- INSIDERSEC Form 4 filed by Vivos Therapeutics Inc.4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- SECSEC Form PRER14A filed by Vivos Therapeutics Inc.PRER14A - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECSEC Form 8-K filed by Vivos Therapeutics Inc.8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity StandardLITTLETON, Colo., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other breathing and sleep-related health conditions, today announced receipt of a letter from the Listing Qualifications staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") on October 20, 2026 stating that the Company currently complies with Listing Rule 5550(b)(1), requiring the Company to maintain stockholders’ equity of at least $2.5 million. The Company previously reported the closin
- SECSEC Form PRE 14A filed by Vivos Therapeutics Inc.PRE 14A - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA ChannelLITTLETON, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company") today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. ("SOD Sciences" or "SOD") and a 50% undivided co-ownership interest in SOD's pseudohypoxia early‑warning test, the "Primed Cell for Chronic Disease" test. In exchange, Vivos issued to SOD 12,000 shares of newly created Series C Convertible Preferred Stock with an aggregate stated value of $12 million. No cash consideration was paid by either party. Through the joint marketing arrangement to be negotiated with SOD following closing and SOD’s marketing relationship
- SECSEC Form 8-K filed by Vivos Therapeutics Inc.8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- SECSEC Form 8-K filed by Vivos Therapeutics Inc.8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia TestLITTLETON, Colo., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that it has entered into a definitive Mutual Stock Purchase and Asset Exchange Agreement to acquire an 11% fully diluted equity interest in SOD Sciences, Inc. and a 50% undivided co-ownership interest in SOD’s proprietary pseudohypoxia early-warning test, in exchange for 12,000 shares of newly created Series C Convert
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth InitiativesLITTLETON, Colo., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other breathing and sleep disorders, today announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6 million annually, beginning in Q4 2026. Parts of the plan have already been implemented, with additional reductions going into effect October 1, 2026. The primary savings in the plan come from staff reductions, vendor relationship changes, negot
- INSIDERSEC Form 4 filed by Director Sokolow Leonard J4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- INSIDERSEC Form 4 filed by Director Johnson Gregg C4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- INSIDERChief Executive Officer Huntsman Ronald Kirk acquired $50,000 worth of Preferred Stock (85,910 units at $0.58) (SEC Form 4)4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- SECAmendment: Vivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K/A - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics Announces Material Debt ReductionLITTLETON, Colo., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a medical device and healthcare services company focused on developing and commercializing diagnostic and treatment methods for patients with obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced that on August 31, 2026, Vivos entered into twelve exchange agreements with Streeterville Capital, LLC, exchanging $2,861,270 of outstanding principal under its secured promissory note (the "Streeterville Note") for 11,445,080 shares of common stock at an exchange price of $0.25 per share. As previously announced o
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
- PRVivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment CenterLITTLETON, Colo., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from obstructive sleep apnea ("OSA") and other health conditions related to breathing and sleep disorders, today announced the execution of definitive collaboration and operating agreements with South Palm Cardiovascular Associates, LLC ("SPCVA") to support the establishment and operation of a regional Sleep & Airway Medicine Center ("SAMC") in Palm Beach County, Florida. The definitive agreements build on th
- INSIDERPrincipal Accounting Officer Amman Bradford K. was granted 250,000 shares, increasing direct ownership by 312,500% to 250,080 units (SEC Form 4)4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
- PRVivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine CentersLITTLETON, Colo., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from obstructive sleep apnea ("OSA") and other sleep disorders, today announced that new OSA patient referrals flowing into its Nevada Sleep & Airway Medicine Centers have increased 212% over the most recent six-week period versus the prior six-week period. Since June 1, the total average weekly number of referrals has risen nearly five-fold and has continued to grow week over week. The Company recently an
- SECVivos Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
VVOS FAQ
11 questionsWhat does Vivos Therapeutics Inc. do?
Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States...What is the latest news on VVOS?
In the last 30 days Quantisnow tracked 13 wire items for VVOS: 6 SEC filings, 4 press releases and news items and 3 insider trades. The most recent was published on November 2, 2026.What is VVOS revenue?
Vivos Therapeutics Inc. (VVOS) reported $20.90M of revenue for the twelve months ended Jun 30, 2026. That is up 45.2% from the year before. Revenue for fiscal 2025 was $17.44M.Is VVOS profitable?
No. Vivos Therapeutics Inc. reported a net loss of $25.53M for the twelve months ended Jun 30, 2026.How much cash and debt does VVOS have?
Vivos Therapeutics Inc. reported $1.77M in cash and cash equivalents and $8.14M of debt on its most recent balance sheet in SEC filings.Where does VVOS stock trade?
Vivos Therapeutics Inc. (VVOS) is listed on NASDAQ.What sector and industry is VVOS in?
Vivos Therapeutics Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Vivos Therapeutics Inc. go public?
Vivos Therapeutics Inc. (VVOS) completed its IPO in 2020.What are analysts saying about VVOS?
Vivos Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Roth Capital: Buy with a $10.00 price target on 2021-08-13. Recent price targets cluster around $10.00.What companies are similar to VVOS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare VVOS side-by-side with any of them on Quantisnow.How can I track VVOS on Quantisnow?
Quantisnow aggregates Vivos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VVOS to receive live email and push alerts on every new disclosure.